A Phase 4 interventional study of Bortezomib and Eltrombopag in Hematological Neoplasms, sponsored by Wei Zhao. Recruiting at 2 sites in China. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Wei Zhao · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing bortezomib in Hematologic Neoplasms — 3 open to participants now, 3 under way, 1 of them phase 3. Bortezomib · Hematologic Neoplasms.
Among the 10 studies testing bortezomib in Hematologic Neoplasms, this one has the largest planned enrollment, is one of 2 that started in 2016, is the only one in phase 4, and was the 8th registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →3 of the 10 studies testing bortezomib in Hematologic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Henry Ford Health System · Sites in United States
Ages 18–65
The First Affiliated Hospital of Soochow University
Ages 18–65
By country, each count listing its studies:
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 1 Day to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 1 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 41 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 10 most frequent:
Wei Zhao is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Wei Zhao has 1 study filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing bortezomib in Hematologic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs based on the opportunistic sampling strategy in children with confirmed or suspected hematological neoplasms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.
Drug: Bortezomib · Drug: Eltrombopag · Drug: Imatinib · Drug: dasatinib · Drug: Pegaspargase · Drug: Anti-Infective Drugs · Drug: PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
bortezomib was administered follow the doctor's advice.
Also known as: Velcade
eltrombopag was administered follow the doctor's advice.
Also known as: promacta
imatinib was administered follow the doctor's advice.
Also known as: Gleevec
dasatinib was administered follow the doctor's advice.
Also known as: sprycel
pegaspargase was administered follow the doctor's advice.
Also known as: Oncaspar
anti-infective drugs was administered follow the doctor's advice.
pegaspargase was administered follow the doctor's advice.
Also known as: PEG-rhG-CSF
change of plasma concentration of bortezomib
To detect the plasma concentrations of bortezomib after administration
Time frame: at(0-0.5)h,(0.5-3)h,(24-48)h,(48-72)h hours after administration
change of plasma concentration of eltrombopag
To detect the plasma concentrations of eltrombopag after administration
Time frame: at (0.5-3)h,(3-6)h,(10-14)h,(20-24)h hours after oral administration
change of plasma concentration of imatinib
To detect the plasma concentrations of imatinib after administration
Time frame: at (0.5-2)h,(2-4)h,(10-14)h,(20-24)h hours after oral administration
change of plasma concentration of dasatinib
To detect the plasma concentrations of dasatinib after administration
Time frame: at(0-0.5)h,(0.5-3)h,(10-14)h,(20-24)h hours after oral administration
change of plasma concentration of pegaspargase
To detect the plasma concentrations of pegaspargase after administration
Time frame: at Day-1,Day(0-1),Day(3-5),Day(8-10),Day(13-14) after administration
plasma concentration of anti-infective drug
To detect the plasma concentrations of anti-infective drug after administration
Time frame: through study completion, an average of 14 days
Not enrolling at this site.
Started Jan 2016 (actual). Primary completion is estimated for Dec 2025, 119 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bortezomib · Eltrombopag · Imatinib · Dasatinib · Pegaspargase · Filgrastim
Wei Zhao